



FOR IMMEDIATE RELEASE

Contact:
Paul Byerley
Chief Executive Officer
+1 320.259.4321
pbyerley@artossinc.com

Artoss, Inc. Announces Record Sales of NanoBone® Bone Graft

Significant sales growth despite Covid-19 pandemic

St. Cloud, MN, October 5, 2020 / -- Artoss, Inc. (St. Cloud, MN), a medical device company that is pioneering the use of advanced bone graft substitutes to treat multiple orthopaedic indications, announced record sales of NanoBone Bone Graft products in the third quarter of 2020.

Paul Byerley, Chief Executive Officer of Artoss, Inc., the exclusive North American distributors for NanoBone®, said, "Through perseverance and diligent effort by our sales management team and independent distributors, we accomplished record sales for the third quarter of 2020. Our team's continued hard work allowed us to achieve this milestone in the middle of a global pandemic. We are especially gratified to see new orthopaedic surgeon users and hospitals embrace the outstanding clinical outcomes and cost savings when using NanoBone as a standalone bone graft substitute."

In addition, Mr. Byerley added that the Company is, "focused on further strengthening our clinical and cost effectiveness propositions through post-market Clinical Registries that were recently established."

The growth in quarterly and annual sales reinforces NanoBone's consistent and cost-effective outcomes in bone grafting in multiple orthopaedic indications. NanoBone achieves these outcomes with no preparation required, excellent handling for surgeons, creation of an osteogenic matrix within 14 days, and clinical and radiographic healing in as little as 8 weeks. The dramatic growth in NanoBone procedures further secures its growing market position as a leader in the bone repair space. There is growing acceptance by surgeons that not all bone graft substitutes are the same, given the rapid osteogenic matrix formation of NanoBone within 14 days.

###

About NanoBone

NanoBone was first cleared by the Food and Drug Administration (FDA) in 2015 after having been successfully used in Europe for ten years. Clinical publications have identified bone graft substitutes as an increasingly important component of many orthopaedic procedures. Consistent healing in orthopaedic procedures is a significant unmet clinical

need and one where NanoBone may provide an effective option.

NanoBone is a commercially available product in the U.S. intended to fill bony voids or gaps of the skeletal system (i.e., extremities, posterolateral spine and pelvis). These osseous defects are surgically created or the result of traumatic injury to the bone and are not intrinsic to the stability of the bony structure. NanoBone[®] SBX Putty resorbs and is replaced with bone during the healing process.

###

About Artoss, Inc.

Artoss, Inc. (St. Cloud, MN) is a medical device company that is a leading distributor of bioidentical bone graft substitutes to treat multiple orthopaedic indications and is dedicated to the development of tools and products for effectively treating a variety of orthopaedic conditions requiring surgical intervention. The company markets, NanoBone Bone Graft Substitute, which gives clinical outcomes comparable to autograft with less postoperative pain and complications. Artoss, Inc. has an experienced management team with extensive experience in orthopaedic medical devices.